A5012573264- Inflammatory Bowel Disease
- Microscopic Colitis
- Diverticular Disease and Complications
- Biosimilars and Bioanalytical Methods
- Celiac Disease Research and Management
- Autoimmune and Inflammatory Disorders
- Eosinophilic Esophagitis
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Colorectal Cancer Surgical Treatments
- Pharmaceutical studies and practices
- Appendicitis Diagnosis and Management
- Gastrointestinal motility and disorders
- Autoimmune and Inflammatory Disorders Research
- Diagnosis and treatment of tuberculosis
- Neuroendocrine Tumor Research Advances
- Phagocytosis and Immune Regulation
- Mycobacterium research and diagnosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Acute Lymphoblastic Leukemia research
- Helicobacter pylori-related gastroenterology studies
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
Gentofte Hospital
2024-2025
Rigshospitalet
2025
University of Copenhagen
2022-2024
Herlev Hospital
2022-2024
Copenhagen University Hospital
2024
Abstract Background Up to 30% of patients with acute severe ulcerative colitis (ASUC) require urgent colectomy despite IV corticosteroids and rescue therapies infliximab or cyclosporin. JAK-inhibitors, like tofacitinib, have emerged as effective treatments for ASUC, but data on postoperative complications are limited.1, 2 Methods We conducted a multicenter, retrospective, case-control (1:2) study hospitalized ASUC who underwent colectomy, comparing treated tofacitinib (cases) prior their...
Abstract Background Despite a growing array of medical treatment options, resection rates for Crohn’s disease (CD) have decreased over time, while re-resection remained stable at approximately one-third in historical cohorts. This study aimed to assess 30-day postoperative outcomes and complication following primary bowel CD patients. Methods encompassed all patients undergoing Eastern Denmark from 2010 2020 (46% the Danish population, n=2,730,000). Clinical characteristics, surgical...
Abstract Background Crohn's disease (CD) is a chronic inflammatory condition that can lead to irreversible intestinal damage. Fibrosis, caused by imbalanced extracellular matrix (ECM) remodeling, difficult manage, as current anti-inflammatory treatments do not prevent or reverse these processes. ECM fragments released during remodeling may serve biomarkers for transmural activity and fibrosis burden. This study evaluated the correlation of serum C3M, PRO-C3, PRO-C16 levels their potential...
Abstract Background Acute severe ulcerative colitis (ASUC) occurs in 25% of patients with (UC) resulting hospital admission and treatment corticosteroids followed by rescue therapy infliximab, if needed. High baseline infliximab clearance at has been associated risk colectomy supporting an intensified regimen case insufficient effect.1 However, a recent randomized controlled trial did not find superior outcomes different regimens.2 We investigated admitted UC have increased infliximab....
Abstract Background The rate of having a resection for patients with Crohn's disease (CD) have decreased over decades, while the rates re-resections seem to been stable around 1/3 in historic cohorts. Re-resection might be influenced by targeted therapies. We aimed investigate re-resection and risk recurrence contemporary cohort effect medical treatment on these parameters. Methods This population-based included all CD undergoing primary intestinal between 2010 2020 Eastern Denmark,...
The influence of concomitant prednisolone on clinical outcomes and safety in infliximab-treated ulcerative colitis (UC) patients is unknown.
Despite advances in the medical treatment of Crohn's disease [CD], many patients will still need bowel resections and face subsequent risk recurrence re-resection. We describe contemporary re-resection rates identify disease-modifying factors for conducted a retrospective, population-based, individual patient-level data cohort study covering 47.4% Danish population, including all CD who underwent primary resection between 2010 2020. Among 631 resected patients, 24.5% second resection, 5.3%...
Abstract Background Treatment failure with biological agents is common in patients ulcerative colitis (UC), but the impact of baseline histological disease activity unknown. We aimed to investigate predictive role histopathological findings for treatment UC patients. Methods This a sub-study Danish IBD Biobank Project. Adult bio-naïve (n=129) were followed prospectively while undergoing treatment. Histological was assessed using Nancy Index and Geboes score intestinal biopsies sampled before...
Abstract Background Biological treatment failure is common in patients with ulcerative colitis (UC), but the predictive value of baseline histological activity unknown. Aims We aimed to investigate associations between and outcomes after biological UC. Methods Adult biological-naïve UC (n = 150) were followed prospectively during treatment. Histological was assessed using Nancy Index Geboes score. Endoscopic Mayo Subscore (MES). Associations multivariable models. histological, endoscopic,...
Existing findings on outcomes of anti-tumor-necrosis-factor (TNF) therapy in patients with inflammatory bowel diseases (IBD) are largely based retrospective studies. We aimed to investigate real-world anti-TNF and predictors thereof a prospective IBD cohort.
Abstract Background The use and cost of biological treatment in patients with inflammatory bowel diseases (IBD) continue to rise. Meanwhile, rates primary non-response (PNR) loss response (LOR) are high. We aimed investigate predictors PNR LOR a real-world cohort bio-naïve IBD patients. Methods This study included, 488 adult (52% UC, 47% CD, 1% IBDU) who initiated completed induction therapy drug from May, 2019 – Oct, 2021 at five university hospitals covering, 2.1 M inhabitants. Clinical...
Abstract Background Data regarding the influence of prednisolone tapering on clinical outcomes among patients with ulcerative colitis (UC) are limited. We aimed to investigate different algorithms effectiveness infliximab (IFX) UC. Methods This Danish retrospective single-center study included all UC who were treated IFX between 2009 and 2019 at Herlev University Hospital. The grouped according tapering: standard (≤5 mg/week), fast (>5 or direct discontinuation after an initial course...